Live webcast on Friday, September 7, 2018, 7.45-9:30 am EDT (1.45-3.30 pm CET)
Jena, Germany, 28 August 2018 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, will host an R&D Day on Hidradenitis Suppurativa (HS) and its scientific and clinical experience with its breakthrough anti-C5a monoclonal antibody IFX-1, on Friday, September 7 in New York City.
InflaRx founders, Prof. Niels Riedemann and Prof. Renfeng Guo will discuss the development of InflaRx's anti-C5a monoclonal antibody technology including its lead drug IFX-1. Based on their in-depth complement research experience, they will share new insights in terminal complement activation mechanisms, and what motivated their choice of the key target C5a. Finally, they will provide an update on the current IFX-1 clinical phase II development in HS, and speak to other C5a mediated disease opportunities.
Evangelos Giamarellos-Bourboulis, MD, PhD, ATTIKON University Hospital in Athens, Greece, and principal investigator of the ongoing phase IIb trial, will discuss Hidradenitis Suppurativa (HS), a devastating auto-inflammatory skin disease with high unmet medical need. Dr. Giamarellos-Bourboulis will address the current treatment landscape and its limitations as well as his first-hand experience in treating HS patients with IFX-1. Dr. Giamarellos-Bourboulis will be available to answer questions at the conclusion of the event.
Evangelos Giamarellos-Bourboulis, MD, PhD is Professor of Internal Medicine in the 4th Department of Internal Medicine at ATTIKON University Hospital in Greece. He leads one of the world’s largest HS outpatient clinics, and played a pivotal role in the development of the first approved therapy in HS. Throughout the years he has advanced the field of HS therapy through an increasing amount of research related to the pathophysiology of the disease. Dr. Giamarellos-Bourboulis has conducted numerous investigator and sponsor initiated clinical trials in HS and is internationally recognized for his important contributions to this field. Besides the HS field, Dr. Giamarellos-Bourboulis is an expert in research and clinical trials in the fields of immunology and severe infections and member of the Steering Committee of the World Sepsis Day. In 2009, he was awarded the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Young Investigator Research Award for his contribution to the field of immunotherapy of sepsis. He is chairing the Hellenic Sepsis Study Group and the Hellenic Sepsis Study Institute. He is the President-Elect of the European Shock Society. Dr. Giamarellos-Bourboulis has published over 350 research and review articles with more than 10,000 citations.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. A live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via email. Please RSVP in advance if you plan to attend in person, as space is limited.
IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has demonstrated control of the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development that has, to date, successfully completed three clinical Phase II studies. In total, more than 150 patients have so far been treated with IFX-1, which was well tolerated. IFX-1 is currently being developed for different inflammatory indications.
About InflaRx N.V.:
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany as well as Ann Arbor, Michigan, USA. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”. For further information please visit www.inflarx.com.
Prof. Dr. Niels C. Riedemann
Chief Executive Officer info[at]inflarx.de
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.